VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor

Details VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor

2006-05-16

2006-05-16

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C514S009100, C514S011400, C514S019300, C530S317000, C530S321000

Reexamination Certificate

active

07045133

ABSTRACT:
Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop 1, 2 or 3 of VEGF-D, and methods of making them are described as well as pharmaceutical compositions containing them and methods utilizing them.

REFERENCES:
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 0467701 (1992-01-01), None
patent: WO 95/34312 (1995-12-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO9807832 (1998-02-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/66954 (1999-12-01), None
patent: WO 00/75176 (2000-12-01), None
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Jan., 2000, TIBTECH 18: 34-39.
Potgens et al, J Biol Chem 269(52): 32879-85, Dec. 1994.
Stacker et al, J Biol Chem 274(45): 32127-26; Nov. 1999.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Stacker et al, J Biol Chem 274(49): 34884-92, 1999.
Walsh et al, Protein Engineering 10(4): 389-98, 1997.
Kiba et al, J Biol Chem 278(15): 13453-61, 2003.
Baldwin et al, J Biol Chem 276(22): 19166-19171, 2001.
Yamada et al, Genomics 42(3):483-8; Jun. 15, 1997.
Le et al, Accession No. T25674, Oct. 1999.
Arja Kaipainen, “Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphathic endothelium during development” Proc. Natl. Acad. Sci, USA, Apr. 1995, vol. 92: 3566-70.
James Lee, “Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4” Proc. Natl. Acad. Sci, USA, Mar. 1996, vol. 93: 1988-92.
J. Taipale, “Vascular Endothelial Growth Factor Receptor-3” Current Topics in Microbiology and Immunology, vol. 237, 1999, vol. 237: 85-96.
Arja Kaipainen, “Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas” Cancer Research, Dec. 1994, vol. 54: 6571-77.
Vladimir Joukov, “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases” The EMBO Journal, 1996, vol. 15(2):290-298.
Marc G. Achen, “Monoclonal antibodies to vascular endothelial growth factor-D block its interactions wtih both VEGF receptor-2 and VEGF receptor-3” Eur. J. Biochemistry, Feb. 2000, vol. 267: 2505-15.
Marc G. Achen, “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)” Proc. National Acad. of Science, Jan. 1998, vol. 95: 548-553.
Steven Stacker, “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics” Nature Medicine, Feb. 2001, vol. 7(2): 186-191.

Affiliated with

Also associated with

Rating

VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3623030